Skip to content

LKQ LKQ Granted (in shares)

Granted (in shares) at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$135.00
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
7K
Essential Utilities logo
Essential UtilitiesWTRG
$193.92K+24.4%
AeroVironment logo
AeroVironmentAVAV
0
Coeur Mining logo
Coeur MiningCDE
3.5M
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$502.97

Other financials

Income statement

See full
Revenue$3.5B+4.3%
Gross profit$1.3B+1.4%
Operating income$217.0M-18.7%
Net income$79.0M-53.3%
EPS (diluted)$0.30-53.8%

Balance sheet

See full
Cash & equivalents$335.0M+47.6%
Total debt$1.5B-3.9%
Total equity$6.5B+4.7%
Total assets$15.1B-2.1%

Cash flow

See full
Operating cash flow-$56.0M-1,767%
CapEx$40.0M-25.9%
Free cash flow-$96.0M-68.4%

Valuation

See full
Market cap$6.57B-31.9%
Enterprise value$7.73B-29.8%
P/E12.7×-1.0×
P/S0.5×-0.2×

Profitability

See full
Gross margin38.3%-0.7pp
Operating margin6.9%-1.5pp
Net margin3.7%-1.4pp
FCF margin5.8%+1.7pp

Returns & leverage

See full
Return on equity8.2%-3.2pp
Debt / equity0.2×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by LKQ in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.

The official record: LKQ’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about LKQ's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LKQ's granted (in shares)?
LKQ (LKQ) reported granted (in shares) of 223.8K in Q4 2025.
How has LKQ's granted (in shares) changed year-over-year?
LKQ's granted (in shares) decreased by 2.1% year-over-year, from 228.6K to 223.8K.
What does granted (in shares) mean?
Quantifies the total volume or value of equity-based awards granted to employees and directors during the reporting period, excluding stock options. This metric provides insight into the company's long-term incentive structure and potential future dilution for shareholders.